(Q39214819)

10 September 2017

1 reference

title

Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions (English)

1 reference

10 September 2017

antimicrobial resistance

1 reference

1 reference

LeBel M

1

1 reference

PubMed ID

2836821

10 September 2017

language of work or name

English

0 references

publication date

1 January 1988

1 reference

10 September 2017

1 reference

10 September 2017

8

1 reference

10 September 2017

1

1 reference

10 September 2017

3-33

1 reference

A Critical Evaluation of Nalidixic Acid in Urinary-Tract Infections

10 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Resistance to nalidixic acid. A misconception due to underdosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

The mode of action of 4-quinolones and possible mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Mutational resistance to 4-quinolone antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Investigations into the mechanism of action of the antibacterial agent norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Combined resistance to quinolones and beta-lactams after in vitro transfer on single drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro evaluation of A-56619 and A-56620, two new quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of ciprofloxacin (Bay o 9867)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Sensitivity patterns of coagulase-negative staphylococci from neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Activity of CI-934 against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Activity of ciprofloxacin against resistant clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

A laboratory assessment of ciprofloxacin and comparable antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

The comparative in-vitro activity of pefloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparative in-vitro activity of ciprofloxacin against non-fermenters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Is ciprofloxacin active against clinically important anaerobes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Activities of new quinoline derivatives against genital pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In-vitro susceptibility of mycobacteria to ciprofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparative in-vitro activity of five fluoroquinolones against mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Antimicrobial Synergism--An Elusive Concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In-vitro study of the activity of ciprofloxacin alone and in combination against strains of Pseudomonas aeruginosa with multiple antibiotic resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Elimination of plasmids by new 4-quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Elimination of plasmids from Enterobacteriaceae by 4-quinolone derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Inhibition of conjugal transfer of R plasmids by pipemidic acid and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Inhibition of R-plasmid transfer in Escherichia coli by 4-quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Determination of norfloxacin and ciprofloxacin concentrations in serum and urine by high-pressure liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of three oral formulations of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Tissue penetration of ciprofloxacin after single and multiple doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Absolute oral bioavailability of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Effect of dose size on bioavailability of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Dose ranging study and constant infusion evaluation of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics and tissue penetration of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of ciprofloxacin after oral and parenteral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Multiple-dose ciprofloxacin dose ranging and kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Single and multiple dose pharmacokinetics of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of intravenously administered ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin concentrations in bone and muscle after oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Concentration of ciprofloxacin in human prostatic tissue after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Penetration of ciprofloxacin into bronchial secretions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Penetration activities of ciprofloxacin into muscle, skin and fat following oral administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Uptake of ciprofloxacin by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Decreased erythrocyte penetration of pefloxacin in cirrhotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of ciprofloxacin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ceftazidime in patients with pseudomonas infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Tobramycin sulfate: a summary of worldwide experience from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Norfloxacin: clinical pharmacology and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Treatment duration for urinary tract infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Treatment of genital chlamydial infection with ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Clinical experience with ciprofloxacin in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Quinolones in chest infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin in the treatment of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Open, prospective study of the clinical efficacy of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin in Salmonella infection and abdominal typhoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Successful treatment with ciprofloxacin of Salmonella typhimurium infection in an immunocompromised host.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a patient with acquired immune deficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Treatment of Salmonella typhi carrier state with ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Treatment of chronic salmonella carriers with ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Impact of oral ciprofloxacin on the faecal flora of healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Effect of oral ciprofloxacin on the faecal flora of healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Successful treatment of Pseudomonas ventriculitis with ciprofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Clinical resistance to long-term oral ciprofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Resistance to ciprofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin-resistant Pseudomonas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin: an overview of adverse experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

The influence of quinolone derivatives on theophylline clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Ciprofloxacin-induced hematuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Treatment of respiratory tract infections with ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Crystalluria and ciprofloxacin, influence of urinary pH and hydration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Tolerance of ciprofloxacin at injection site, systemic safety and effect on electroencephalogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Norfloxacin disposition after sequentially increasing oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

Enoxacin--a potent inhibitor of theophylline metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04058.X

10.1002/J.1875-9114.1988.TB04058.X

21 January 2018

Identifiers

DOI

1 reference

release_67p5qbcyb5gbxpoxgjxgpmak3m

10 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/67p5qbcyb5gbxpoxgjxgpmak3m

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

2836821

1 reference

PubMed ID

2836821